Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A rare hereditary angioedema characterized by potentially life-threatening episodes of subcutaneous and/or submucosal edema without urticaria and with normal levels and function of C1 esterase inhibitor. Patients present with prolonged attacks which last for approximately two to five days and may include nonpitting edema of the skin, severe abdominal symptoms such as pain and swelling, and/or respiratory distress due to upper respiratory airways involvement. Affected locations and frequency of attacks differ slightly between subtypes. Estrogen-containing oral contraceptives and pregnancy are precipitating factors, especially in patients with a factor XII mutation.
Biomarker and diagnostic research for hereditary angioedema with normal C1Inh has been reported in the published literature.
No clinical trials have been registered for hereditary angioedema with normal C1Inh.
69 publications have been identified in PubMed for hereditary angioedema with normal C1Inh. Research spans Review / Meta-Analysis (36%), Case Report / Case Series (22%), and Epidemiology / Natural History (22%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 21 | 36% |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 11:22 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Patient case studies
13 |
22% |
Disease patterns and progression | 13 | 22% |
Testing and diagnosis research | 6 | 10% |
Clinical study results | 4 | 7% |
Laboratory research | 2 | 3% |
Boch K (2026). [PMID: 41782867](https://pubmed.ncbi.nlm.nih.gov/41782867/). *Front Immunol*. [Epidemiology / Natural History]
Guan Z (2026). [PMID: 41560114](https://pubmed.ncbi.nlm.nih.gov/41560114/). *Medicine (Baltimore)*. [Case Report / Case Series]
Banerji A (2026). [PMID: 41794053](https://pubmed.ncbi.nlm.nih.gov/41794053/). *J Allergy Clin Immunol*. [Clinical Trial Publication]
Buckland MS (2026). [PMID: 41180162](https://pubmed.ncbi.nlm.nih.gov/41180162/). *J Allergy Clin Immunol Glob*. [Clinical Trial Publication]
Casanova M (2026). [PMID: 41723522](https://pubmed.ncbi.nlm.nih.gov/41723522/). *Orphanet J Rare Dis*. [Case Report / Case Series]
Horváth HR (2026). [PMID: 41832580](https://pubmed.ncbi.nlm.nih.gov/41832580/). *Orphanet J Rare Dis*. [Basic Science / Preclinical]
Jones D (2026). [PMID: 41533199](https://pubmed.ncbi.nlm.nih.gov/41533199/). *Clin Exp Med*. [Epidemiology / Natural History]
Magerl M (2026). [PMID: 41788693](https://pubmed.ncbi.nlm.nih.gov/41788693/). *Allergol Select*. [Epidemiology / Natural History]
Davis-Lorton M (2026). [PMID: 41582175](https://pubmed.ncbi.nlm.nih.gov/41582175/). *Allergy Asthma Clin Immunol*. [Epidemiology / Natural History]
Xu Y (2026). [PMID: 40209692](https://pubmed.ncbi.nlm.nih.gov/40209692/). *Int Arch Allergy Immunol*. [Review / Meta-Analysis]